Alemtuzumab

Search with Google Search with Bing

Information
Drug Name
Alemtuzumab
Description
Entry(CIViC)
1
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
chronic lymphocytic leukemia TP53 DELETERIOUS MUTATION TP53 DELETERIOUS MUTATION B Predictive Supports Sensitivity/Response Somatic 2 14726385 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Thirty-six patients with CLL were treated with ale... TP53 TP53 DELETERIOUS MUTATION TP53 DELETERIOUS MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03504241 Active, not recruiting Phase 1 Tolerance by Engaging Antigen During Cellular Homeostasis July 30, 2018 December 2029
NCT02629120 Active, not recruiting Phase 1/Phase 2 High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease December 17, 2015 November 30, 2026
NCT03182426 Active, not recruiting Phase 1/Phase 2 Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM) August 15, 2017 December 31, 2025
NCT03989466 Active, not recruiting Phase 1 Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia January 15, 2020 December 31, 2026
NCT01361711 Active, not recruiting Phase 2 Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia June 2011 May 2027
NCT02061800 Active, not recruiting Phase 1/Phase 2 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant June 3, 2013 July 2026
NCT00977691 Active, not recruiting Phase 1/Phase 2 Haploidentical PBMC Transplant for Severe Congenital Anemias December 14, 2009 September 10, 2026
NCT00408447 Active, not recruiting Phase 2 Stem Cell Transplant in Sickle Cell Disease and Thalassemia September 2004 February 2025
NCT03821610 Active, not recruiting Phase 2 A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) November 22, 2018 November 22, 2027
NCT00061568 Active, not recruiting Phase 1/Phase 2 Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias July 16, 2004 January 31, 2026
NCT06310343 Active, not recruiting ADAs to Alemtuzumab April 25, 2022 November 30, 2025
NCT01659606 Active, not recruiting Phase 2 Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita July 2012 December 2034
NCT00078559 Completed Phase 1/Phase 2 Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults November 2003 February 2010
NCT00086775 Completed Phase 2 Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia July 2003 October 2009
NCT00089349 Completed Phase 2 Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia July 2004
NCT00098670 Completed Phase 2 Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia October 2004 February 2011
NCT00104975 Completed Phase 1 Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer February 2005 May 2008
NCT00105235 Completed Phase 2 Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients June 2005 March 2011
NCT00109993 Completed Phase 2 Campath-1H + FK506 and Methylprednisolone for GVHD January 2005 May 2007
NCT00113269 Completed Phase 4 Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients May 2005 March 2009
NCT00118352 Completed Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer March 2005 May 26, 2015
NCT00143065 Completed Phase 2 Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma August 2005 July 2009
NCT00147381 Completed Phase 3 Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection January 2004 July 2011
NCT00153985 Completed Phase 2 Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies March 2004 July 2009
NCT00162851 Completed Phase 2 Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia April 2003 July 2006
NCT00175253 Completed Phase 2 Alemtuzumab Induction in Islet Transplantation November 2005 April 2012
NCT00175266 Completed Phase 2 Islet Transplantation Using Campath-1H and Infliximab Induction
NCT03806387 Completed Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment March 1, 2017 June 30, 2021
NCT00183248 Completed Phase 1/Phase 2 Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients September 2004 November 2009
NCT00230282 Completed Phase 2 Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia July 2004 October 2011
NCT00240994 Completed Phase 2 Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients January 2005 November 2009
NCT00260689 Completed Phase 2 Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia November 28, 2005 May 4, 2016
NCT00274976 Completed Phase 2 Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine September 2002 August 2009
NCT00276809 Completed Phase 2 Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia June 2001 September 2004
NCT00278213 Completed Phase 2 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia September 2002 December 2009
NCT00281983 Completed Phase 1/Phase 2 Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia June 2000 July 2010
NCT00292760 Completed Phase 2 A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
NCT00301834 Completed Phase 2 Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders January 2005 September 2011
NCT00316810 Completed Phase 3 Simultaneous Pancreas-kidney Transplantation With Campath Protocol April 2006 June 2011
NCT00323323 Completed Phase 1 CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas March 2004 October 2016
NCT00328198 Completed Phase 2 Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia May 2006 August 2011
NCT00330252 Completed Phase 1 Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL May 2006 January 2014
NCT00331162 Completed Phase 4 Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation February 2005 November 28, 2011
NCT03302754 Completed N/A Precision Dosing of Alemtuzumab October 5, 2017 March 10, 2019
NCT03135249 Completed Phase 4 Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis May 1, 2018 November 4, 2020
NCT00383448 Completed Phase 2 HSCT for High Risk Inherited Inborn Errors September 2006 September 2014
NCT00410657 Completed Phase 2 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant July 2006
NCT00436904 Completed Phase 2 Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia December 2004 November 2011
NCT02867800 Completed Phase 1 Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease July 2016 December 30, 2023
NCT02766465 Completed Phase 2 Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) November 2016 May 2, 2023
NCT00454480 Completed Phase 2/Phase 3 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes August 2006
NCT00458523 Completed Phase 2 Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission December 2006 February 2008
NCT02689453 Completed Phase 1 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) January 19, 2017 June 15, 2021
NCT00520130 Completed Phase 1/Phase 2 Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System October 30, 2007 December 31, 2018
NCT00525603 Completed Phase 2 CFAR Study in Patients With Chronic Lymphocytic Leukemia June 2005 July 2011
NCT00525876 Completed N/A Non-Myeloablative Allogeneic Stem Cell Transplantation January 2005 September 2010
NCT00530348 Completed Phase 3 Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One August 2007 April 2011
NCT00553098 Completed Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders June 2006
NCT02497404 Completed Phase 2 Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR February 13, 2015 June 17, 2021
NCT00562328 Completed Phase 2 Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia January 2008 December 18, 2014
NCT00565773 Completed Phase 2 Belatacept Post Depletional Repopulation to Facilitate Tolerance December 2007 July 1, 2017
NCT00565981 Completed Phase 2 A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response March 2004 February 13, 2008
NCT00566696 Completed Phase 2 Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies December 14, 2007 February 6, 2020
NCT00578643 Completed Phase 2 Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease March 2004 November 24, 2017
NCT02472054 Completed Phase 1/Phase 2 Treatment of Familiar Lymphohistiocytosis June 29, 2015 May 20, 2020
NCT02419378 Completed Phase 4 Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential June 2015 November 2020
NCT00669318 Completed Phase 2 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma July 2008 May 2014
NCT00006390 Completed Phase 2 Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia July 5, 2001
NCT02385110 Completed Phase 2 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis September 23, 2015 January 24, 2023
NCT02059239 Completed Phase 1/Phase 2 Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma June 4, 2014 June 15, 2020
NCT01877837 Completed Phase 3 Stem Cell Transplantation for Sickle Cell Anemia June 2011 September 2021
NCT00775632 Completed Phase 2 Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants October 2008 September 2010
NCT01806337 Completed Phase 2 CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma July 2003 February 2011
NCT01729494 Completed Phase 4 Belatacept Early Steroid Withdrawal Trial September 2012 December 2019
NCT00858117 Completed Phase 2 A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL September 26, 2005 January 24, 2013
NCT01625351 Completed Phase 1 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas August 20, 2012 February 10, 2020
NCT01395316 Completed Phase 4 Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis June 2011 July 2017
NCT01392079 Completed Phase 2 Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine February 2008 March 2016
NCT01269385 Completed Phase 1/Phase 2 Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia January 2011 June 2015
NCT00923182 Completed Phase 1 A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia February 2010 August 2011
NCT00930553 Completed Phase 3 An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab August 2009 February 2016
NCT00930605 Completed Phase 2 The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) January 2005 July 2008
NCT00935792 Completed Phase 1/Phase 2 Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma July 2009 December 2015
NCT01256398 Completed Phase 2 Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia December 14, 2010 November 15, 2021
NCT00951457 Completed Phase 1/Phase 2 Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) March 2009 August 6, 2012
NCT01172418 Completed Phase 4 Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols February 2006 May 2010
NCT01120028 Completed Phase 2/Phase 3 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy September 2010 March 2020
NCT00021151 Completed N/A Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia January 2000 May 2002
NCT00027560 Completed Phase 2 Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer July 2001 April 2009
NCT00040846 Completed Phase 2 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies November 2001 December 2009
NCT00046683 Completed Phase 3 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia July 2001 June 2006
NCT00004857 Completed Phase 2 Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia January 2000 February 2010
NCT00057967 Completed Phase 2 Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome July 2000 July 26, 2010
NCT00061048 Completed Phase 2 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma May 2003 July 2012
NCT00061945 Completed Phase 1/Phase 2 Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia June 2003 October 2012
NCT00073879 Completed N/A Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation April 2003 April 2004
NCT00074282 Completed Phase 2 Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL April 14, 2005 May 6, 2018
NCT01082939 Completed Phase 2 Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) December 2002 January 2011
NCT01208337 Completed Phase 2 Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation April 2007 November 2014
NCT01186640 Completed Phase 2 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) June 2010 May 2014
NCT06084780 Not yet recruiting Phase 2 Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) October 2024 December 31, 2025
NCT06358638 Recruiting Phase 2 Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY April 2024 September 2054
NCT00692939 Recruiting Phase 1/Phase 2 Autologous Stem Cell Transplantation for Crohn's Disease June 26, 2012 December 2026
NCT01499888 Recruiting Phase 1/Phase 2 Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) November 11, 2011 May 2025
NCT01962415 Recruiting Phase 2 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT February 4, 2014 November 2024
NCT02105766 Recruiting Phase 2 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure April 21, 2014 December 31, 2024
NCT02162420 Recruiting N/A Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia January 10, 2015 July 2026
NCT03214354 Recruiting Phase 2 Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor July 5, 2017 July 2028
NCT03477500 Recruiting Phase 3 Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) March 21, 2018 March 21, 2026
NCT03500731 Recruiting Phase 1/Phase 2 Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure April 19, 2018 December 2026
NCT03579875 Recruiting Phase 2 Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders November 13, 2018 January 5, 2029
NCT03630211 Recruiting Phase 2 Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis July 31, 2018 August 1, 2025
NCT03653338 Recruiting Phase 1/Phase 2 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias August 2, 2018 August 1, 2026
NCT03910452 Recruiting Early Phase 1 Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide October 28, 2019 June 15, 2034
NCT04018937 Recruiting Phase 2 Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation March 22, 2019 January 2027
NCT04232085 Recruiting Phase 2 Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide February 12, 2020 December 31, 2026
NCT04339777 Recruiting Phase 2 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity September 22, 2020 November 30, 2027
NCT05357482 Recruiting Phase 1/Phase 2 Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia May 12, 2022 November 1, 2033
NCT05384756 Recruiting Phase 1 TMLI and Alemtuzumab for Treatment of Sickle Cell Disease July 13, 2022 December 1, 2026
NCT05463133 Recruiting Phase 1/Phase 2 Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists July 8, 2022 December 31, 2032
NCT05501756 Recruiting Phase 2 Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation January 11, 2023 August 31, 2028
NCT05688436 Recruiting A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate September 24, 2021 January 17, 2031
NCT01982175 Suspended Phase 2 Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia July 2011 June 2022
NCT01013961 Terminated Phase 2 Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia April 27, 2011 April 14, 2015
NCT02013375 Terminated Phase 2 SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD April 10, 2014 September 7, 2018
NCT01191749 Terminated Phase 2 Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) August 2010 November 2013
NCT00983528 Terminated Phase 1/Phase 2 Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia September 2009 September 2011
NCT01213329 Terminated Phase 4 Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab February 2006 April 2009
NCT00947388 Terminated Phase 1 Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) November 2008 March 2013
NCT00818961 Terminated Phase 2 Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer May 2005 March 2012
NCT01679041 Terminated Phase 2 High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment November 2012 November 2013
NCT00177138 Terminated Phase 4 Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation July 2004 November 2006
NCT00166712 Terminated Phase 4 A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression April 2005 April 2010
NCT00881556 Terminated Early Phase 1 Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) August 20, 2009 September 2015
NCT00698685 Terminated Phase 2 Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation January 23, 2006 April 26, 2011
NCT01436305 Terminated Phase 2 Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation September 2011 April 2015
NCT00637390 Terminated Phase 1 A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. March 2008 October 2010
NCT01465334 Terminated Phase 2 Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL December 2011 January 2017
NCT00051701 Terminated Phase 1/Phase 2 Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma December 2002 August 2005
NCT00618540 Terminated Phase 2 Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis January 2007 May 2013
NCT01712945 Terminated Phase 1/Phase 2 Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis June 2012 October 2017
NCT00801931 Terminated Phase 1/Phase 2 Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders September 6, 2007 May 5, 2009
NCT00555048 Terminated Phase 1/Phase 2 Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer September 2007
NCT02653196 Terminated Early Phase 1 A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors September 2015 August 2017
NCT02678143 Terminated Phase 1 Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease April 26, 2016 November 16, 2021
NCT00472433 Terminated Phase 2 The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias March 2007 May 2009
NCT00453193 Terminated Phase 2 Alemtuzumab and Pentostatin In T-cell Neoplasms September 2004 March 2010
NCT00441025 Terminated Phase 2 The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL September 2006 August 2009
NCT03132584 Terminated Phase 1 Cyclophosphamide and Alemtuzumab In Lymphoma July 30, 2017 January 30, 2018
NCT00781781 Terminated Phase 2 Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning July 2008 December 2011
NCT01875237 Terminated Phase 1/Phase 2 Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene December 27, 2013 March 7, 2017
NCT00771602 Terminated Phase 2 Alemtuzumab + Rituximab Consolidation in CLL August 2008 December 2010
NCT04971005 Terminated Phase 2 Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial August 27, 2021 February 4, 2022
NCT03250169 Terminated Neurofilaments for NEDA Assessing in MS August 1, 2017 January 28, 2022
NCT00871546 Terminated Phase 2 SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) March 2009 December 2010
NCT03421756 Terminated Early Phase 1 Stem Cell Transplant in Patients With Severe Sickle Cell Disease March 29, 2018 May 15, 2022
NCT01596699 Terminated Phase 2 Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation May 24, 2012 June 2019
NCT01518153 Terminated Phase 2 Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) February 2012 August 2014
NCT00262925 Terminated Phase 2 Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia June 2006 February 2013
NCT01624714 Unknown status Phase 1 Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects September 2012 September 2017
NCT00725231 Unknown status Phase 3 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP February 2008 March 2014
NCT00720447 Unknown status Phase 2 Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma November 2008
NCT00562068 Unknown status Phase 1 Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma May 2007
NCT02529839 Unknown status N/A Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS) October 2015 October 2017
NCT00363090 Unknown status Phase 1/Phase 2 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma September 2006
NCT00337519 Unknown status Phase 2 Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia January 2003 April 2009
NCT03193086 Unknown status The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients January 1, 2017 March 31, 2020
NCT00336206 Unknown status N/A Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia July 2006 October 2009
NCT00157274 Unknown status Phase 2 Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome July 2005 July 2008
NCT00986557 Unknown status Phase 2 T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant September 2009
NCT00908180 Unknown status Phase 2 Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma July 2009
NCT01333358 Unknown status Phase 3 Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients May 2011 March 2014
NCT00907036 Unknown status Phase 2 Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma July 2009
NCT00895739 Unknown status Phase 2 Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure June 2006
NCT01405807 Unknown status Phase 4 Alemtuzumab for ANCA Associated Refractory Vasculitis February 2011 March 2014
NCT01446484 Unknown status Phase 1/Phase 2 Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection October 2011 November 2014
NCT04154735 Withdrawn Phase 2 Autologous Transplant Targeted Against Crohn's November 2019 March 2024
NCT00081068 Withdrawn Phase 2 Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia January 2004
NCT00085449 Withdrawn Phase 1/Phase 2 Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer May 2006 January 2007